Inactive

See combined synopsis/solicitation for more information. The materials shall be for the initial (screen) immunoassay for the detection of both d-amphetamine (DAMP) and d-methamphetamine (DMETH) in uri... See combined synopsis/solicitation for more information. The materials shall be for the initial (screen) immunoassay for the detection of both d-amphetamine (DAMP) and d-methamphetamine (DMETH) in urine when present individually, or in combination, at a concentration equal to or greater than 500 ng/mL. The reagent shall be compatible with the Beckman Coulter AU5800 Series Clinical Chemistry Analyzers in use at the Department of Defense (DOD) Forensic Toxicology Drug Testing Laboratories (FTDTLs), without modification of the equipment. The immunoassay procedure is limited to a two reagent assay procedure. A vendor’s reagent proposal which requires a separate pretreatment of each testing specimen prior to testing on the analyzer will not be considered acceptable. The reagent shall be compatible with the optimal throughput of the analyzer systems and shall not interfere with the optimum performance of the other immunoassay procedures performed on these instruments. The reagent shall not impose additional maintenance, servicing, or calibration requirements for the optimum performance of the contractor’s reagent on the analyzer.